1.	ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: POLARIS2009-001, NCT01287585
2.	Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LUD2009-007, 10-161, Pro00022622, NCT01266018
3.	A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 6837, 2006-004592-35, NCT01279967
4.	Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: POLARIS2010-001, NCT01497925
5.	Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Argininousccinate Synthetase Deficient Advanced Tumors Phase: Phase I Type: Treatment Status: Approved-not yet active Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: POLARIS2012-005, NCT01665183